

BLISS INTIMATE OIL

Batch Specific Information

| | | |
|---------------------------------|-----------------------------------|-------------------------------|
| Product Name | Bliss Intimate Oil | |
| Product Description | 250mg active cannabinoids in 60mL | |
| Lot Number | 21AHSS130 | |
| Expiration Date | 05/2023 | |
| Date of Production (Batch Date) | 06/2021 | |
| Batch Size: | 360kg | Quantity Produced: 6137 units |

Raw Ingredients

| Ingredient | Manufacturer | Lot Number |
|----------------------------|-----------------------|--------------------------|
| ALMOND OIL | INTEGRITY INGREDIENTS | 691C2310 |
| SHEA OIL | AAK | 0002211784 |
| COCONUT OIL | INTEGRITY INGREDIENTS | 6845 |
| COCOA SEED BUTTER | INTEGRITY INGREDIENTS | 735919 |
| FULL SPECTRUM HEMP EXTRACT | ECOFIBRE | CKS1-CT-LEX19-01 |
| PEPPERMINT OIL | INTEGRITY INGREDIENTS | 18921819 |
| TOCOPHEROL | BASF | 0022963929 0021636892 |
| BLACK PEPPER OIL | INTEGRITY INGREDIENTS | 33952 |
| FRAGRANCE | ORCHIDIA | 0245104 1133131 |

Manufactured By:

Ananda Health
PO Box 399
Georgetown, KY 40324
833-791-2511

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

June 21, 2021

PO BOX 399
Georgetown, KY - 40324

Order No. 524605
Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Cannabinoid Profile
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF12D012
Analysis Date June 16, 2021 to June 21, 2021

| Cannabinoid | mg/g | % | mg/ml |
|-------------------------------|-------|-------|-------|
| Δ8-THC | ND | ND | ND |
| Δ9-THC | 0.22 | 0.022 | 0.20 |
| Δ9-THCA | ND | ND | ND |
| THCV | ND | ND | ND |
| THCVA | ND | ND | ND |
| CBD | 4.83 | 0.483 | 4.42 |
| CBDA | ND | ND | ND |
| CBC | 0.26 | 0.026 | 0.24 |
| CBCA | ND | ND | ND |
| CBDV | ND | ND | ND |
| CBG | <LOQ | <LOQ | <LOQ |
| CBGA | ND | ND | ND |
| CBN | ND | ND | ND |
| Total THC | 0.22 | 0.022 | 0.20 |
| Total CBD | 4.83 | 0.483 | 4.42 |
| Total Cannabinoids | 5.31 | 0.531 | 4.86 |
| Total Active Cannabinoids | 5.31 | 0.531 | 4.86 |
| g/ml Conversion Factor | 0.916 | | |

✓AST 6/29/21

Reported by
Anresco, Inc.

Limit of Detection: 0.067 mg/g
Limit of Quantitation: 0.2 mg/g
ND = None Detected
<LOQ = Below Limit of Quantitation
<LOD = Below Limit of Detection




Marybel Mendez
Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".

June 21, 2021


PO BOX 399
Georgetown, KY - 40324

Order No. 524605
Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Heavy Metals  Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF 24E020
Analysis Date June 16, 2021 to June 21, 2021

| Analyte | LOD/LOQ (µg/g) | Findings (µg/g) | Limit (µg/g) | Status |
|---------|----------------|-----------------|--------------|--------|
| Arsenic | 0.02/0.05 | ND | 1.5 | Pass |
| Cadmium | 0.02/0.05 | ND | 0.5 | Pass |
| Mercury | 0.02/0.05 | ND | 3 | Pass |
| Lead | 0.02/0.05 | ND | 0.5 | Pass |

Reported by
Anresco, Inc.

ND = None Detected



Marybel Mendez
Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".

June 21, 2021

PO BOX 399
Georgetown, KY - 40324

Order No. 524605
Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Micro Screen - Ananda Hemp
Analysis Date June 16, 2021 to June 21, 2021

| Analyte | Findings | Units | Method |
|----------------------|----------|-------|--------------------|
| Standard Plate Count | <10 | cfu/g | FDA BAM |
| Yeast | <10 | cfu/g | AOAC 2014.05 |
| Mold | <10 | cfu/g | AOAC 2014.05 |
| Coliforms | <10 | cfu/g | FDA BAM - ECC Agar |
| E. coli | <10 | cfu/g | FDA BAM - ECC Agar |
| Enterobacteriaceae | <10 | cfu/g | AOAC 2003.01 |
| Salmonella | Negative | /1g | AOAC 2016.01 |

Reported by
Anresco, Inc.




Marybel Mendez
Compliance Manager

June 21, 2021

✓ ASD
6/29/21

If there are any questions with this report, please contact "compliance@anresco.com".

June 21, 2021


PO BOX 399
 Georgetown, KY - 40324

Order No. 524605
 Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Pesticides Screen  **Pass**
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF 21P030
Analysis Date June 16, 2021 to June 21, 2021

| Analyte | LOD/LOQ (µg/g) | Findings (µg/g) | Limit (µg/g) | Status |
|---------------------|----------------|-----------------|--------------|--------|
| Abamectin | 0.04/0.10 | ND | 0.3 | Pass |
| Acephate | 0.02/0.06 | ND | 5.0 | Pass |
| Acequinocyl | 0.04/0.10 | ND | 4.0 | Pass |
| Acetamiprid | 0.02/0.06 | ND | 5.0 | Pass |
| Aldicarb | 0.02/0.06 | ND | 0.02 | Pass |
| Azoxystrobin | 0.02/0.06 | ND | 40.0 | Pass |
| Bifenazate | 0.02/0.06 | ND | 5.0 | Pass |
| Bifenthrin | 0.04/0.10 | ND | 0.5 | Pass |
| Boscalid | 0.02/0.06 | ND | 10.0 | Pass |
| Captan | 0.20/0.06 | ND | 5.0 | Pass |
| Carbaryl | 0.02/0.06 | ND | 0.5 | Pass |
| Carbofuran | 0.02/0.06 | ND | 0.02 | Pass |
| Chlorantraniliprole | 0.02/0.06 | ND | 40.0 | Pass |
| Chlordane | 0.02/0.06 | ND | 0.02 | Pass |
| Chlorfenapyr | 0.02/0.08 | ND | 0.02 | Pass |
| Chlorpyrifos | 0.02/0.06 | ND | 0.02 | Pass |
| Clofentezine | 0.02/0.06 | ND | 0.5 | Pass |
| Coumaphos | 0.02/0.06 | ND | 0.02 | Pass |
| Cyfluthrin | 0.10/0.30 | ND | 1.0 | Pass |
| Cypermethrin | 0.10/0.30 | ND | 1.0 | Pass |
| Daminozide | 0.02/0.06 | ND | 0.02 | Pass |
| DDVP (Dichlorvos) | 0.02/0.06 | ND | 0.02 | Pass |
| Diazinon | 0.02/0.06 | ND | 0.2 | Pass |
| Dimethoate | 0.02/0.06 | ND | 0.02 | Pass |
| Dimethomorph | 0.02/0.06 | ND | 20.0 | Pass |
| Ethoprop(hos) | 0.02/0.06 | ND | 0.02 | Pass |
| Etofenprox | 0.02/0.06 | ND | 0.02 | Pass |
| Etoxazole | 0.02/0.06 | ND | 1.5 | Pass |
| Fenhexamid | 0.02/0.06 | ND | 10.0 | Pass |
| Fenoxycarb | 0.02/0.06 | ND | 0.02 | Pass |
| Fenpyroximate | 0.02/0.06 | ND | 2.0 | Pass |
| Fipronil | 0.02/0.06 | ND | 0.02 | Pass |

✓AST
6/29/21

If there are any questions with this report, please contact "compliance@anresco.com".

| Analyte | LOD/LOQ (µg/g) | Findings (µg/g) | Limit (µg/g) | Status |
|-------------------------|----------------|-----------------|--------------|--------|
| Flonicamid | 0.02/0.06 | ND | 2.0 | Pass |
| Fludioxanil | 0.02/0.06 | ND | 30.0 | Pass |
| Hexythiazox | 0.02/0.06 | ND | 2.0 | Pass |
| Imazalil | 0.02/0.06 | ND | 0.02 | Pass |
| Imidacloprid | 0.02/0.06 | ND | 3.0 | Pass |
| Kresoxim Methyl | 0.02/0.06 | ND | 1.0 | Pass |
| Malathion | 0.02/0.06 | ND | 5.0 | Pass |
| Metalaxyl | 0.02/0.06 | ND | 15.0 | Pass |
| Methiocarb | 0.02/0.06 | ND | 0.02 | Pass |
| Methomyl | 0.02/0.06 | ND | 0.1 | Pass |
| Methyl parathion | 0.02/0.06 | ND | 0.02 | Pass |
| Mevinphos | 0.02/0.06 | ND | 0.02 | Pass |
| Myclobutanil | 0.02/0.06 | ND | 9.0 | Pass |
| Naled | 0.02/0.06 | ND | 0.5 | Pass |
| Oxamyl | 0.02/0.06 | ND | 0.2 | Pass |
| Paclobutrazol | 0.02/0.06 | ND | 0.02 | Pass |
| Pentachloronitrobenzene | 0.04/0.10 | ND | 0.2 | Pass |
| Permethrins | 0.10/0.30 | ND | 20.0 | Pass |
| Phosmet | 0.02/0.06 | ND | 0.2 | Pass |
| Piperonyl Butoxide | 0.02/0.06 | ND | 8.0 | Pass |
| Prallethrin | 0.04/0.10 | ND | 0.4 | Pass |
| Propiconazole | 0.02/0.06 | ND | 20.0 | Pass |
| Propoxur | 0.02/0.06 | ND | 0.02 | Pass |
| Pyrethrins | 0.10/0.30 | ND | 1.0 | Pass |
| Pyridaben | 0.02/0.06 | ND | 3.0 | Pass |
| Spinetoram | 0.02/0.06 | ND | 3.0 | Pass |
| Spinosad | 0.02/0.06 | ND | 3.0 | Pass |
| Spiromesifen | 0.04/0.10 | ND | 12.0 | Pass |
| Spirotetramat | 0.02/0.06 | ND | 13.0 | Pass |
| Spiroxamine | 0.02/0.06 | ND | 0.02 | Pass |
| Tebuconazole | 0.02/0.06 | ND | 2.0 | Pass |
| Thiacloprid | 0.02/0.06 | ND | 0.02 | Pass |
| Thiamethoxam | 0.02/0.06 | ND | 4.5 | Pass |
| Trifloxystrobin | 0.02/0.06 | ND | 30.0 | Pass |

✓ ADT
6/24/21

Reported by
Anresco, Inc.

ND = None Detected





Marybel Mendez
 Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".

ANALYTICAL RESULTS

Analysis Mycotoxins Screen  **Pass**

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Method MF 21P030

Analysis Date June 16, 2021 to June 21, 2021

| Analyte | LOD/LOQ (µg/kg) | Findings (µg/kg) | Limit (µg/kg) | Status |
|------------------|-----------------|------------------|---------------|--------|
| Aflatoxin B1 | 2/5 | ND | - | - |
| Aflatoxin B2 | 2/5 | ND | - | - |
| Aflatoxin G1 | 2/5 | ND | - | - |
| Aflatoxin G2 | 2/5 | ND | - | - |
| Total Aflatoxins | 8/20 | ND | 20 | Pass |
| Ochratoxin A | 6/18 | ND | 20 | Pass |

Reported by
Anresco, Inc.

ND = None Detected




Marybel Mendez
Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".

June 21, 2021

PO BOX 399
Georgetown, KY - 40324

Order No. 524605
Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Micro Screen - Ananda Hemp
Analysis Date June 16, 2021 to June 21, 2021

| Analyte | Findings | Units | Method |
|----------------------|----------|-------|--------------------|
| Standard Plate Count | <10 | cfu/g | FDA BAM |
| Yeast | <10 | cfu/g | AOAC 2014.05 |
| Mold | <10 | cfu/g | AOAC 2014.05 |
| Coliforms | <10 | cfu/g | FDA BAM - ECC Agar |
| E. coli | <10 | cfu/g | FDA BAM - ECC Agar |
| Enterobacteriaceae | <10 | cfu/g | AOAC 2003.01 |
| Salmonella | Negative | /1g | AOAC 2016.01 |

✓
6/29/21

Reported by
Anresco, Inc.




Marybel Mendez
Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".

June 21, 2021

PO BOX 399
 Georgetown, KY - 40324

Order No. 524605
 Sample No. 1086250

SAMPLE INFORMATION

Description BLISS INTIMATE OIL 250 IN 60
Lot Number 21AHSS130
PO# 399
Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)
Received June 16, 2021

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method USP OVI<467>
Analysis Date June 16, 2021 to June 21, 2021

| Analyte | LOD/LOQ (ppm) | Findings (ppm) | Limit (ppm) | Status |
|--------------------------------------|---------------|----------------|-------------|--------|
| 1,2-Dichloroethane | 0.1/1 | ND | 1 | Pass |
| Acetone | 50/150 | ND | 5000 | Pass |
| Acetonitrile | 4/12 | ND | 410 | Pass |
| Benzene | 0.1/1 | ND | 1 | Pass |
| n-Butane | 48/160 | ND | 5000 | Pass |
| Chloroform | 0.1/1 | ND | 1 | Pass |
| Ethanol | 67/200 | ND | 5000 | Pass |
| Ethyl acetate | 27/80 | ND | 5000 | Pass |
| Ethyl ether | 17/50 | ND | 5000 | Pass |
| Ethylene oxide | 0.5/1 | ND | 1 | Pass |
| n-Heptane | 1/4 | ND | 5000 | Pass |
| n-Hexane | 2/10 | ND | 290 | Pass |
| Isopropyl alcohol | 33/100 | ND | 5000 | Pass |
| Methanol | 50/150 | ND | 3000 | Pass |
| Methylene chloride | 0.5/1 | ND | 1 | Pass |
| n-Pentane | 2/6 | ND | 5000 | Pass |
| Propane | 10/33 | ND | 5000 | Pass |
| Toluene | 10/30 | ND | 890 | Pass |
| Total xylenes (ortho-, meta-, para-) | 30/90 | ND | 2170 | Pass |
| Trichloroethylene | 0.1/1 | ND | 1 | Pass |

✓ A27
 6/29/21

Reported by
Anresco, Inc.

ND = None Detected




Marybel Mendez
 Compliance Manager

June 21, 2021

If there are any questions with this report, please contact "compliance@anresco.com".